Refine
Year of publication
Document Type
- Article (41)
- Conference Proceeding (3)
- Preprint (1)
Has Fulltext
- yes (45)
Is part of the Bibliography
- no (45)
Keywords
- ataxia telangiectasia (5)
- Ataxia telangiectasia (4)
- ATM (3)
- Ataxia-telangiectasia (3)
- asthma (3)
- lung function (3)
- primary immunodeficiency (3)
- Allergic asthma (2)
- Cytokines (2)
- Neurodegeneration (2)
- body plethysmography (2)
- cystic fibrosis (2)
- malignancy (2)
- Albumin ratio (1)
- Allergen immunotherapy (1)
- Allergic rhinitis (1)
- Allergoid (1)
- Aspergillus fumigatus (1)
- Ataxia score (1)
- Atm (1)
- Biomarker (1)
- Bronchial inflammation (1)
- CD23 (1)
- CD45RA naïve lymphocytes (1)
- CRP (1)
- CVID (1)
- Cell distribution (1)
- Cerebrospinal fluid (1)
- Cumulative dose (1)
- Curvilinear dose response (1)
- D-dimer (1)
- Disease progression (1)
- Double-blind placebo-controlled trial (1)
- Epidemiologie (1)
- Erregernachweis (1)
- European Society for Immunodeficiencies (ESID) (1)
- Exercise challenge (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced asthma (1)
- Exercise-induced bronchoconstriction (1)
- Exhaled nitric oxide (1)
- F508del homozygous (1)
- Fever (1)
- Forced expiratory volume in 1 s (1)
- German PID-NET registry (1)
- Grass pollen (1)
- GvHD (1)
- HSCT (1)
- HbA1c (1)
- Healthcare worker (1)
- Hexavalent vaccine (1)
- House dust mite allergy (1)
- IgA deficiency (1)
- IgE (1)
- IgG substitution therapy (1)
- Immunodeficiency (1)
- Immunoglobulins (1)
- Induced sputum (1)
- LABAs (1)
- Labordiagnostik (1)
- Local IgE (1)
- Local allergic rhinitis (1)
- Longchain polyunsaturated fatty acids (1)
- Lymphopenia Mortality (1)
- Methacholine challenge test (1)
- Mortality (1)
- Neurofilament light chain (1)
- NfL (1)
- Non-allergic-rhinitis (1)
- OGTT (1)
- PID prevalence (1)
- Paracetamol (1)
- Pertussis (1)
- Pneumococcal conjugate vaccine (1)
- Prophylaxis (1)
- Respimat® Soft Mist™ Inhaler (1)
- Respiratorische Infekte (1)
- SARS-CoV-2 (1)
- Smart nebulizer (1)
- T-lymphocytes (1)
- TNF inhibitors (1)
- Ultrasonic nebulizer (1)
- Vaccine uptake rate (1)
- Viruspneumonien (1)
- acute lung injury (1)
- allergen immunotherapy (1)
- allergic rhinitis (1)
- asthma phenotypes (1)
- ataxia score (1)
- autovaccine (1)
- basic mechanisms (1)
- bio imaging (1)
- biologics (1)
- bioluminescence (1)
- birch pollen allergoid (1)
- bronchial allergen challenge (1)
- bronchial allergen provocation (1)
- bronchiolitis obliterans syndrome (1)
- cancer surveillance (1)
- chronic inflammation (1)
- clinical immunology (1)
- combined immunodeficiency (1)
- cumulative dose (1)
- demonstration of the infectious agent (1)
- desensitization (1)
- device handling (1)
- diabetes (1)
- diabetes therapy (1)
- dose response curve (1)
- epidemiology (1)
- gap junction protein alpha 4-genotype (1)
- granulomas (1)
- granulomatous inflammation (1)
- haploidentical (1)
- healthcare worker (1)
- hepatic steatosis (1)
- hospitalization (1)
- house dust mite allergy (1)
- immune deficiency (1)
- immunologic (1)
- inflammation (1)
- inflammatory markers (1)
- inhalation flow profiles (1)
- inhaled steroids (1)
- laboratory diagnostic (1)
- ligelizumab (1)
- liver disease (1)
- long-acting β2-agonists (1)
- lung disease (1)
- lung disease phenotype (1)
- mesenchymal stromal/stem cells (1)
- miRNA (1)
- neurodegeneration (1)
- omalizumab (1)
- pertussis (1)
- phenotype/genotype relation (1)
- pollen allergy (1)
- postinfectious bronchiolitis obliterans (1)
- pre-emptive allogeneic hematopoietic stem cell transplantation (1)
- pre-school asthma (1)
- precision medicine (1)
- preschool asthma (1)
- preschool children (1)
- primary immunodeficiency (PID) (1)
- qRT-PCR (1)
- radio sensitivity (1)
- readmission rates (1)
- real-world evidence (1)
- registry for primary immunodeficiency (1)
- respiratory disease (1)
- respiratory failure (1)
- respiratory infections (1)
- safety (1)
- severe uncontrolled asthma (1)
- spirometry (1)
- stem cell transplantation (1)
- subcutaneous immunotherapy (1)
- sublingual immunotherapy (1)
- tailored treatment schedule (1)
- tiotropium (1)
- tolerability (1)
- tolerance (1)
- tracking (1)
- vaccine uptake rate (1)
- virus pneumonia (1)
Institute
Ataxia telangiectasia (A-T) is a primary immunodeficiency with mutations in the gene encoding the A-T mutated (ATM) protein that interacts with immune, hematopoietic, and endocrine targets resulting in broad multi-systemic clinical manifestations with a devastating outcome. Apart from a progressive neurodegenerative disorder, A-T leads to significantly increased susceptibility to malignancies. It is a matter of discussion whether pre-emptive allogeneic hematopoietic stem cell transplantation (alloHSCT) using a reduced intensity conditioning regimen would be an option to restore immune-competence and prevent malignancy, as shown in animal models, because conventional treatment protocols of malignant diseases using radio- and/or chemotherapy have a high rate of therapy-related morbidity and mortality in these patients. We present the course of the disease, including immune reconstitution and neurological outcome following pre-emptive alloHSCT in a 4-year-old boy with A-T on a 6 year follow-up. Our manuscript provides a proof-of-concept of alloHSCT as an individual pre-emptive treatment strategy from which some A-T patients might benefit.
Tiotropium as an add-on treatment option for severe uncontrolled asthma in preschool patients
(2021)
Background: Toddlers with asthma suffer disproportionally more than school-aged children from exacerbations with emergency visits and hospital admissions despite inhaled corticosteroid (ICS) treatment. A recent trial for children ≤ 5 years showed tolerability of tiotropium and potential to reduce asthma-related events.
Methods: We conducted a retrospective analysis of electronic outpatient records (2017‒2019) of children < 6 years treated with ICS plus long-acting β2-agonists (LABAs) plus tiotropium as an add-on for uncontrolled severe asthma. The primary endpoint was a comparison of systemic corticosteroid (SCS) prescriptions 6 months before and after ICS/LABA/tiotropium start. Secondary endpoints included physician visits, hospitalisations and antibiotic prescriptions. We compared outcomes with children without asthma matched for age, sex, season and screening date.
Results: Compared with a mean 2.42 (95% CI: 1.75, 3.36) SCS courses per patient within 6 months prior to ICS/LABA/tiotropium, 0.74 (95% CI: 0.25, 1.08) SCS courses per patient were prescribed within 6 months after starting ICS/LABA/tiotropium (P< 0.001). Physician visits dropped from 9.23 (95% CI: 7.15, 12.72) to 5.76 (95% CI: 3.10, 7.70) per patient (P< 0.01). Nineteen hospitalisations were recorded 6 months before ICS/LABA/tiotropium compared with one hospitalisation after (P< 0.01). A mean 1.79 antibiotic courses (95% CI: 1.22, 2.23) per patient were prescribed before ICS/LABA/tiotropium compared with 0.74 (95% CI: 0.22, 1.00) after ICS/LABA/tiotropium (P< 0.001). Hospitalisation rates for patients at observation end were not statistically different from healthy controls before/after matching.
Interpretation: Our retrospective study showed that adding tiotropium to ICS/LABA is a new treatment option for patients with severe preschool asthma; however, larger confirmatory studies are needed.
Rationale: Postinfectious bronchiolitis obliterans (PIBO) is a rare, chronic respiratory condition, which follows an acute insult due to a severe infection of the lower airways. Objectives: The objective of this study was to investigate the long-term course of bronchial inflammation and pulmonary function testing in children with PIBO. Methods: Medical charts of 21 children with PIBO were analyzed retrospectively at the Children's University Hospital Frankfurt/Main Germany. Pulmonary function tests (PFTs) with an interval of at least 1 month were studied between 2002 and 2019. A total of 382 PFTs were analyzed retrospectively and per year, the two best PFTs, in total 217, were evaluated. Additionally, 56 sputum analysis were assessed and the sputum neutrophils were evaluated. Results: The evaluation of the 217 PFTs showed a decrease in FEV1 with a loss of 1.07% and a loss in z score of −0.075 per year. FEV1/FVC decreased by 1.44 per year. FVC remained stable, showing a nonsignificant increase by 0.006 in z score per year. However, FEV1 and FVC in L increased significantly with FEV1 0.032 L per cm and FVC 0.048 L/cm in height. Sputum neutrophils showed a significant increase of 2.12% per year. Conclusion: Our results demonstrated that in patients with PIBO pulmonary function decreased significantly showing persistent obstruction over an average follow-up period of 8 years. However, persistent lung growth was revealed. In addition, pulmonary inflammation persisted clearly showing an increasing amount of neutrophils in induced sputum. Patients did not present with a general susceptibility to respiratory infections.
A high incidence of thromboembolic events associated with high mortality has been reported in severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections with respiratory failure. The present study characterized post-transcriptional gene regulation by global microRNA (miRNA) expression in relation to activated coagulation and inflammation in 21 critically ill SARS-CoV-2 patients. The cohort consisted of patients with moderate respiratory failure (n = 11) and severe respiratory failure (n = 10) at an acute stage (day 0–3) and in the later course of the disease (>7 days). All patients needed supplemental oxygen and severe patients were defined by the requirement of positive pressure ventilation (intubation). Levels of D-dimers, activated partial thromboplastin time (aPTT), C-reactive protein (CRP), and interleukin (IL)-6 were significantly higher in patients with severe compared with moderate respiratory failure. Concurrently, next generation sequencing (NGS) analysis demonstrated increased dysregulation of miRNA expression with progression of disease severity connected to extreme downregulation of miR-320a, miR-320b and miR-320c. Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis revealed involvement in the Hippo signaling pathway, the transforming growth factor (TGF)-β signaling pathway and in the regulation of adherens junctions. The expression of all miR-320 family members was significantly correlated with CRP, IL-6, and D-dimer levels. In conclusion, our analysis underlines the importance of thromboembolic processes in patients with respiratory failure and emphasizes miRNA-320s as potential biomarkers for severe progressive SARS-CoV-2 infection.
Ataxia telangiectasia (A-T) is a progressive and life-limiting disease associated with cerebellar ataxia due to progressive cerebellar degeneration. In addition to ataxia, which is described in detail, the presence of chorea, dystonia, oculomotor apraxia, athetosis, parkinsonism, and myoclonia are typical manifestations of the disease. The study aimed to evaluate the specificity and sensitivity of neurofilament light chain (NfL) as a biomarker of neurodegeneration in relation to SARA score. In this prospective trial, one visit of 42 A-T patients aged 1.3–25.6 years (mean 11.6 ± 7.3 years) was performed, in which NfL was determined from serum by ELISA. Additionally, a neurological examination of the patients was performed. Blood was collected from 19 healthy volunteers ≥ 12 years of age. We found significantly increased levels of NfL in patients with A-T compared to healthy controls (21.5 ± 3.6 pg/mL vs. 9.3 ± 0.49 pg/mL, p ≤ 0.01). There was a significant correlation of NfL with age, AFP, and SARA. NfL is a new potential progression biomarker in blood for neurodegeneration in A-T which increases with age.